Injectables continue to dominate US aesthetics market
Injectables account for just over half of total sales in the aesthetics market, closely followed by body treatments, according to Kline & Company
Injectable treatments, such as Botox and fillers, continue to dominate the aesthetics market in the US, according to a report by research firm Kline & Company called Professional Aesthetics: U.S. Market Analysis and Opportunities.
While injectables account for just over half of total sales in the aesthetics market, they are closely followed by body treatments, a category which is growing by approximately 20% in 2013. Growth can partially be put down to the popularity of alternatives to liposuction; body contouring and cellulite reduction treatments are emerging as increasingly popular procedures.
Kline & Company has also identified three key factors driving growth in this market: greater awareness of in-office treatments and their benefits; less down time and discomfort, with a host of treatments that can sometimes address multiple concerns; and increased distribution.
The non-surgical cosmetics procedures market has grown by almost 500% over the last 20 years, while 2012 sales of professional aesthetic products grew by 7.5%, according to the company.